Literature DB >> 26202659

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.

S E Keating1, C Ní Chorcora1, M M Dring1, R L Stallings2, A O'Meara3, C M Gardiner1.   

Abstract

Neuroblastoma is the most common extra-cranial solid tumour in children. Natural killer (NK) cells are innate lymphocytes that are known to mediate the direct cytotoxicity of neuroblastoma tumour cells. Natural variation in the highly polymorphic killer immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands results in considerable diversity in NK cell function. As the early onset of neuroblastoma suggests the contribution of genetic factors, we investigated if individual KIR genes, combined KIR gene haplotypes or compound KIR-HLA ligand genotypes could influence susceptibility to neuroblastoma. Genotype analysis of the KIR genes as well as their three major HLA class I ligand groups, HLA-C1, HLA-C2 and HLA-Bw4, was carried out in a cohort of 201 neuroblastoma patients compared with 240 healthy control subjects using polymerase chain reaction with sequence-specific primers. We found a significant increase in the frequency of KIR2DL2 (P = 0.019) as well as KIR2DS2 (P = 0.008) in patients with neuroblastoma compared with the healthy control group. While the incidence of the least inhibitory compound KIR-HLA-C genotype, KIR2DL3 in the presence of HLA-C1 was slightly reduced in neuroblastoma patients, this did not reach statistical significance (P = 0.069). In summary, while KIR-HLA compound genotypes have previously been implicated in predicting treatment outcomes in neuroblastoma, here we show that the presence of the individual KIR genes, KIR2DL2 and KIR2DS2, irrespective of HLA-C genotype is associated with the onset of this embryonal malignancy.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  human leukocyte antigen; killer immunoglobulin-like receptor; natural killer cell; neuroblastoma

Mesh:

Substances:

Year:  2015        PMID: 26202659     DOI: 10.1111/tan.12608

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

2.  Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Authors:  Nikolai Siebert; Christian Jensen; Sascha Troschke-Meurer; Maxi Zumpe; Madlen Jüttner; Karoline Ehlert; Silke Kietz; Ina Müller; Holger N Lode
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

Review 3.  Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.

Authors:  Hakim Medjouel Khlifi; Sophie Guia; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

4.  Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Authors:  Amy K Erbe; Wei Wang; Lakeesha Carmichael; KyungMann Kim; Eneida A Mendonça; Yiqiang Song; Dustin Hess; Patrick K Reville; Wendy B London; Arlene Naranjo; Jacquelyn A Hank; Mitchell B Diccianni; Ralph A Reisfeld; Stephen D Gillies; Katherine K Matthay; Susan L Cohn; Michael D Hogarty; John M Maris; Julie R Park; M Fevzi Ozkaynak; Andrew L Gilman; Alice L Yu; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2017-10-02       Impact factor: 12.531

Review 5.  Regulation of Natural Killer Cell Function by STAT3.

Authors:  Nicholas A Cacalano
Journal:  Front Immunol       Date:  2016-04-11       Impact factor: 7.561

Review 6.  The Impact of KIR Polymorphism on the Risk of Developing Cancer: Not as Strong as Imagined?

Authors:  Danillo G Augusto
Journal:  Front Genet       Date:  2016-06-28       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.